SCHEMBL23461027

SCHEMBL23461027

CC(C)(C)[C@H](NC(=O)c1ccc2ccccc2c1OCc1ccc(Br)cc1)C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR2 P25025 4/20 0.49
RAB9A P51151 2/20 0.45
MAPT P10636 3/20 0.43
TP53 P04637 1/20 0.43
LMNA P02545 3/20 0.40
ALDH1A1 P00352 2/20 0.40
GAA P10253 2/20 0.40
KDM4E B2RXH2 1/20 0.40
MAPK1 P28482 1/20 0.40
HTT P42858 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
PYGL P06737 1/20 0.39
CYP2C9 P11712 1/20 0.39
HDAC3 O15379 1/20 0.37
HDAC4 P56524 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC7 Q8WUI4 1/20 0.37
HDAC2 Q92769 1/20 0.37
HDAC10 Q969S8 1/20 0.37
HDAC11 Q96DB2 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23461031 1.00 CXCR2 (0.49) CXCR2RAB9AMAPTTP53LMNA
SCHEMBL25548737 0.88 CXCR2 (0.64) CXCR2MAPTLMNAALDH1A1GAA
SCHEMBL25549891 0.88 CXCR2 (0.64) CXCR2MAPTLMNAALDH1A1GAA
SCHEMBL23461024 0.88 CXCR2 (0.48) CXCR2RAB9AMAPTLMNAALDH1A1
SCHEMBL23461026 0.88 CXCR2 (0.48) CXCR2RAB9AMAPTLMNAALDH1A1
SCHEMBL38147031 0.88 LMNA (0.51) CXCR2RAB9AMAPTLMNAALDH1A1
SCHEMBL23460879 0.88 LMNA (0.51) CXCR2RAB9AMAPTLMNAALDH1A1
SCHEMBL23460884 0.88 LMNA (0.51) CXCR2RAB9AMAPTLMNAALDH1A1
SCHEMBL23461206 0.87 CXCR2 (0.47) CXCR2MAPTLMNAALDH1A1GAA
SCHEMBL23461205 0.87 CXCR2 (0.47) CXCR2MAPTLMNAALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630498-B2 Arylamides and methods of use thereof GENZYME CORPORATION (US) 2026-05-19 US disclosed
US-20230159438-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION 2023-05-25 US disclosed
US-20230159438-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION 2023-05-25 US disclosed
US-20230159438-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION 2023-05-25 US disclosed
WO-2021113806-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION (US) 2021-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159438-A1 ARYLAMIDES AND METHODS OF USE THEREOF CFTR, AADAC, ARSA CXCR2 1205/4885RAB9A 1870/4885MAPT 4871/4885
US-12630498-B2 Arylamides and methods of use thereof CFTR, CLIC1, CLCN2 CXCR2 63/4885RAB9A 284/4885MAPT 4884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.